Skip to main content

Table 2 Univariate Cox proportional hazard model of overall survival by each variable

From: Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy

Baseline Characteristics

HR (95% CI)

p-value

Chemotherapy

HR (95% CI)

p-value

Age

0.978 (0.958–1.000)

0.047

Regimen

 

0.941

Gender

 

0.111

 Platinum + FU

1

 

 Male

1

 

 Taxane + FU

1.336 (0.643–2.776)

0.437

 Female

1.464 (0.916–2.339)

 

 Platinum + Taxane + FU

1.116 (0.569–2.188)

0.750

cT stage

 

0.734

 Taxane + Platinum

1.003 (0.511–1.969)

0.994

 Serosa negative

1

 

 Others

0.904 (0.354–2.306)

0.832

 Serosa positive

1.107 (0.616–1.988)

 

Best response

  

cN stage

 

0.743

 Overall

 

0.201

 N0/N1

1

 

  CR/PR

1

 

 N2/N3

1.109 (0.597–2.061)

 

  SD/PD

1.359 (0.849–2.175)

 

Type of distant metastasis

 

0.065

 Local region

 

0.576

 Peritoneal carcinomatosis

1

 

  CR/PR

1

 

 Liver metastasis

0.407 (0.166–0.994)

0.049

  SD/PD

1.142 (0.717–1.817)

 

 Distant LN metastasis

1.025 (0.590–1.780)

0.930

 Metastatic site

 

0.013

 Krukenberg tumor

4.423 (1.004–19.487)

0.049

  CR/PR

1

 

 Any combination

0.900 (0.467–1.735)

0.753

  SD/PD

2.105 (1.171–3.783)

 

NLR (Neut/lympho)

1.349 (0.837–2.177)

0.219

Preop. response

  

SII (PLT*Neut/lympho)

1.252 (0.776–2.019)

0.357

 Overall

 

0.635

Albumin

 

0.986

  CR/PR

1

 

 low

1

 

  SD/PD

1.119 (0.704–1.777)

 

 normal

1.006 (0.480–2.108)

 

 Local region

 

0.875

   

  CR/PR

1

 
   

  SD/PD

0.963 (0.602–1.540)

 
   

 Metastatic site

 

0.020

   

  CR/PR

1

 
   

  SD/PD

1.850 (1.103–3.103)

 
   

Number of Cycles of Chemotherapy

0.970 (0.930–1.013)

0.167

   

  ≤ 6 cycles

1

0.746

   

  > 6 cycles

0.925 (0.578–1.480)

 

Pre-Operation

HR (95% CI)

p-value

Surgical Outcomes

HR (95% CI)

p-value

BMI

 

0.004

Peritoneal infiltration

 

0.002

 Normal

1

 

 No

1

 

 Underweight

3.538 (1.607–7.789)

0.002

 Yes

2.181 (1.343–3.540)

 

 Overweight & obese

1.073 (0.647–1.778)

0.786

Metastasectomy

 

0.252

Change in CEA level

 

0.009

 No

1

 

 Stable

1

 

 Yes

1.507 (0.747–3.039)

 

 Improved

0.410 (0.193–0.868)

0.020

Extent of gastrectomy

 

0.008

 Worse

4.174 (1.255–13.881)

0.020

 TG

1

 

 NA

0.856 (0.446–1.646)

0.642

 DG

0.521 (0.322–0.842)

 

Change in CA19–9 level

 

0.399

Extent of LND

 

0.402

 Stable

1

 

  < D2

1

 

 Improved

1.020 (0.437–2.381)

0.963

  ≥ D2

0.802 (0.480–1.343)

 

 Worse

0.907 (0.282–2.911)

0.869

Complete Macroscopic Resection

 

< 0.001

 NA

0.580 (0.309–1.089)

0.090

 Yes

1

 

Pre_op cT stage

 

0.069

 No

2.348 (1.471–3.748)

 

 Serosa negative

1

 

pT stage

 

0.002

 Serosa positive

1.537 (0.967–2.444)

 

 Serosa negative (pT1–3)

1

 

Pre_op cN stage

 

0.567

 Serosa positive (pT4a/b)

2.109 (1.311–3.393)

 

 N0/N1

1

 

pN stage

 

0.121

 N2/N3

1.155 (0.705–1.894)

 

 pN0/N1

1

 

Time interval to surgery

 

0.926

 pN2/N3

1.480 (0.901–2.430)

 

  ≤ 24 weeks

1

 

Lauren classification

 

0.013

  > 24 weeks

0.926 (0.584–1.468)

 

 Intestinal

1

 
   

 Diffuse

1.960 (1.204–3.190)

0.007

   

 Others

0.867 (0.361–2.079)

0.748

   

Postoperative chemotherapy

 

0.172

   

 No

1

 
   

 Yes

1.629 (0.809–3.281)

 
  1. LN lymph node, NLR neutrophil lymphocyte ratio, SII systematic immune-inflammation index, CR complete response, PR partial response, SD stable disease, PD progressive disease, BMI body mass index, CEA carcinoembryonic antigen, CA19–9 carbohydrate antigen 19–9, TG total gastrectomy, DG distal gastrectomy, LND lymph node dissection, FU fluoropyrimidine
  2. The bold represents statistical significance